These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 9529075)

  • 1. Enhanced protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2.
    Wortham C; Grinberg L; Kaslow DC; Briles DE; McDaniel LS; Lees A; Flora M; Snapper CM; Mond JJ
    Infect Immun; 1998 Apr; 66(4):1513-20. PubMed ID: 9529075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.
    Nguyen CT; Kim SY; Kim MS; Lee SE; Rhee JH
    Vaccine; 2011 Aug; 29(34):5731-9. PubMed ID: 21696869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae.
    Xin W; Li Y; Mo H; Roland KL; Curtiss R
    Infect Immun; 2009 Oct; 77(10):4518-28. PubMed ID: 19687204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.
    Li B; Chen X; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Wu Y
    Microb Pathog; 2018 Oct; 123():115-119. PubMed ID: 29959043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
    Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ
    Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection.
    Arulanandam BP; Lynch JM; Briles DE; Hollingshead S; Metzger DW
    Infect Immun; 2001 Nov; 69(11):6718-24. PubMed ID: 11598043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
    Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
    Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against systemic fatal pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein A (PspA).
    Katsurahara T; Hotomi M; Yamauchi K; Billal DS; Yamanaka N
    J Infect Chemother; 2008 Dec; 14(6):393-8. PubMed ID: 19089550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection.
    Yamamoto M; McDaniel LS; Kawabata K; Briles DE; Jackson RJ; McGhee JR; Kiyono H
    Infect Immun; 1997 Feb; 65(2):640-4. PubMed ID: 9009325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae.
    Nayak AR; Tinge SA; Tart RC; McDaniel LS; Briles DE; Curtiss R
    Infect Immun; 1998 Aug; 66(8):3744-51. PubMed ID: 9673257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous pro- and anti-inflammatory cytokines differentially regulate an in vivo humoral response to Streptococcus pneumoniae.
    Khan AQ; Shen Y; Wu ZQ; Wynn TA; Snapper CM
    Infect Immun; 2002 Feb; 70(2):749-61. PubMed ID: 11796608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant BCG expressing a PspA-PdT fusion protein protects mice against pneumococcal lethal challenge in a prime-boost strategy.
    Goulart C; Rodriguez D; Kanno AI; Lu YJ; Malley R; Leite LC
    Vaccine; 2017 Mar; 35(13):1683-1691. PubMed ID: 28242071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic immunization with the region encoding the alpha-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae.
    Bosarge JR; Watt JM; McDaniel DO; Swiatlo E; McDaniel LS
    Infect Immun; 2001 Sep; 69(9):5456-63. PubMed ID: 11500417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses.
    Miyaji EN; Dias WO; Tanizaki MM; Leite LC
    FEMS Immunol Med Microbiol; 2003 Jun; 37(1):53-7. PubMed ID: 12770760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the antibody response elicited by immunization with pneumococcal surface protein A (PspA) as recombinant protein or DNA vaccine and analysis of protection against an intranasal lethal challenge with Streptococcus pneumoniae.
    Vadesilho CF; Ferreira DM; Moreno AT; Chavez-Olortegui C; Machado de Avila RA; Oliveira ML; Ho PL; Miyaji EN
    Microb Pathog; 2012; 53(5-6):243-9. PubMed ID: 22981893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A.
    Langermann S; Palaszynski SR; Burlein JE; Koenig S; Hanson MS; Briles DE; Stover CK
    J Exp Med; 1994 Dec; 180(6):2277-86. PubMed ID: 7964500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccine.
    Kang HY; Srinivasan J; Curtiss R
    Infect Immun; 2002 Apr; 70(4):1739-49. PubMed ID: 11895935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broad protective immune responses elicited by bacterium-like particle-based intranasal pneumococcal particle vaccine displaying PspA2 and PspA4 fragments.
    Lu J; Guo J; Wang D; Yu J; Gu T; Jiang C; Kong W; Wu Y
    Hum Vaccin Immunother; 2019; 15(2):371-380. PubMed ID: 30235046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.
    Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y
    Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae.
    Wu HY; Nahm MH; Guo Y; Russell MW; Briles DE
    J Infect Dis; 1997 Apr; 175(4):839-46. PubMed ID: 9086139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.